Section Arrow
Quote
TLX.NASDAQ
- Telix Pharmaceuticals Ltd.
Quotes are at least 15-min delayed:2025/06/05 22:06 EDT
Last
 17.74
+0.26 (+1.49%)
Day High 
18.13 
Prev. Close
17.48 
1-M High
18.8721 
Volume 
8.17K 
Bid
15.6
Ask
17.8
Day Low
17.178 
Open
18.13 
1-M Low
15.545 
Market Cap 
5.85B 
Currency USD 
P/E 186.16 
%Yield -- 
10-SMA 16.79 
20-SMA 16.76 
50-SMA 16.91 
52-W High 30.36 
52-W Low 13.61 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.14/0.69
Enterprise Value
6.41B
Balance Sheet
Book Value Per Share
1.09
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
783.21M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0393-0.0068-14.75%-- 
CLRBCellectar Biosciences0.399201-0.062499-13.54%-- 
RXRXRecursion Pharmaceuticals4.56-0.35-7.13%-- 
GLYCGlycoMimetics0.1994-0.0106-5.05%-- 
SCNIScinai Immunotherapeutics Ltd.3.07+0.55+21.83%1.21PE
Quotes are at least 15-min delayed：2025/06/05 22:06 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.